SCHEMBL16163258

SCHEMBL16163258

COc1ccc(CN2C(=O)C3(CCCC3)Cc3ccccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
OPRL1 P41146 1/20 0.49
MEN1 O00255 2/20 0.49
CASP3 P42574 2/20 0.49
KMT2A Q03164 2/20 0.49
APAF1 O14727 1/20 0.49
GAA P10253 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
SCN9A Q15858 2/20 0.48
SIGMAR1 Q99720 5/20 0.48
BCL2L11 O43521 1/20 0.48
CMA1 P23946 1/20 0.47
DRD2 P14416 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100711 0.95 L3MBTL1 (0.53) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL16163267 0.95 L3MBTL1 (0.53) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL10686202 0.86 POLB (0.52) L3MBTL1OPRL1MEN1KMT2AGAA
SCHEMBL26086688 0.84 L3MBTL1 (0.54) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL23674985 0.82 L3MBTL1 (0.52) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL30100716 0.82 L3MBTL1 (0.52) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL5218062 0.79 L3MBTL1 (0.49) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL31398257 0.79 MAPT (0.48) L3MBTL1MEN1CASP3KMT2AAPAF1
SCHEMBL25284810 0.79 MAPT (0.48) L3MBTL1OPRL1MEN1CASP3KMT2A
SCHEMBL30414194 0.79 MAPT (0.48) L3MBTL1OPRL1MEN1CASP3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809575-B2 Pharmaceutical compounds ReViral Limited (GB) 2017-11-07 US disclosed
EP-2776416-B1 PHARMACEUTICAL COMPOUNDS RE VIRAL LTD (GB) 2016-01-13 EP disclosed
US-20140308282-A1 PHARMACEUTICAL COMPOUNDS re: Viral Ltd (GB) 2014-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308282-A1 PHARMACEUTICAL COMPOUNDS CYP2S1, H1-2, CBR1 L3MBTL1 3695/4885OPRL1 1247/4885MEN1 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.